IMS Health catches layoff bug

Call it the ripple effect. Making a living off pharmaceutical companies suddenly isn't so lucrative: IMS Health, the market research company responsible for so much of the hard data on drug sales, is laying off about 10 percent of its work force.

The company sells detailed market data and medical data to drug makers. That info is mostly used by sales departments--which of course have been shrinking like the Arctic ice lately. Guess it goes to show that layoffs can be contagious.

- here's the article from The Wall Street Journal

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.